



Post Authorisation Assessments

Carprox vet 50 mg Tablets for Dogs

Vm 01656/4012

16 May 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance. (NI)
20 April 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). (GB)
27 January 2026	Submission of a Ph. Eur. CEP for an active substance. (NI)
29 December 2025	Submission of a Ph. Eur. CEP for an active substance. (GB)
29 October 2025	Removal of Distributor: Dechra Veterinary Product A/S, Mekuvej 9, DK-7171 Uldum, Denmark.
22 October 2025	One-off alignment of the product information with version 9.0* of the QRD templates.
11 January 2024	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
16 June 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number. (NI)
07 June 2023	Submission of an updated certificate of suitability. (NI)
24 February 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
28 December 2022	Updated certificate of suitability from an already approved manufacturer.
08 March 2022	Minor change to an approved test procedure for the active substance.
16 December 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
12 November 2021	Minor changes to an approved test procedure of the finished product.
22 April 2020	Minor change in the manufacturing process of the finished product. Minor change in the manufacturing process of the finished product.
19 March 2020	Addition of a manufacturer responsible for batch release including batch control/testing. Addition of a manufacturing site of the finished product.
16 December 2019	Deletion of manufacturing site for a finished product. Addition of a secondary packaging site of the finished product. Addition of a primary packaging site of the finished product.

10 December 2019	Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.
07 November 2019	Change in the manufacturer of a starting material used in the manufacturing process of the active substance.
11 June 2019	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
10 May 2017	Minor change to the restricted part of an Active Substance Master File.
04 December 2015	Deletion of a manufacturing site.
06 August 2015	Renewal – UK as CMS.
08 September 2014	Change in the manufacturing process of the finished product.
16 May 2014	Changes to the manufacturing process for the active substance.
26 September 2013	Change of distributor.
20 June 2013	Change of name of product from 'Rycarfa 50mg Tablets for Dogs' to 'Carprox vet 50mg Tablets for Dogs'.
11 February 2013	To update the ASMF for an already approved ASM.
23 November 2012	Addition of a manufacturing site responsible for primary and secondary packaging. Extension of the finished product shelf life from 2 years to 3 years.
20 April 2011	Repeat Use Comm – UK as CMS.